Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Benralizumab 30 mg q.4 Weeks	400
Overall Study	STARTED	Benralizumab 30 mg q.8 Weeks	398
Overall Study	STARTED	Placebo	407
Overall Study	Received Treatment	Benralizumab 30 mg q.4 Weeks	399
Overall Study	Received Treatment	Benralizumab 30 mg q.8 Weeks	398
Overall Study	Received Treatment	Placebo	407
Overall Study	COMPLETED	Benralizumab 30 mg q.4 Weeks	354
Overall Study	COMPLETED	Benralizumab 30 mg q.8 Weeks	358
Overall Study	COMPLETED	Placebo	367
Overall Study	NOT COMPLETED	Benralizumab 30 mg q.4 Weeks	46
Overall Study	NOT COMPLETED	Benralizumab 30 mg q.8 Weeks	40
Overall Study	NOT COMPLETED	Placebo	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01928771/flow